Grace Therapeutics price target raised to $11 from $8 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Grace Therapeutics (GRCE) to $11 from $8 and keeps a Buy rating on the shares following the company’s Phase 3 STRIVE-ON data for GTX-104, which showed a numerical advantage on the primary and positive trends on many secondaries. The firm cites now 90% probability of success in the model as the company is entering the regulatory phase.